NTT Presents at the Short Shorts Film Festival & Asia 2022
NTT Corporation (“NTT”) screened the “International Conference for Visualizing our Future brought about by Technological Innovation feat. IOWN” at the Short Shorts Film Festival & Asia 2022 (SSFF & Asia 2022), one of the largest international short film festivals in Asia recognized by the U.S. Academy Awards. The conference featured a discussion between NTT, experts of various fields, and international directors who have won the Grand Prix at SSFF & Asia about a vision of the future influenced by technological innovation like IOWN1.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220721005622/en/
(Graphic: Business Wire)
After filmmakers from around the world watched the screening, NTT issued a call for short films featuring the theme of our ideal lives created alongside scientific and technological innovation. From the entries, we will create one short film that best captures the theme.
You can watch the conference on the official SSFF & Asia 2022 website.
NTT is working toward the realization of a smart society founded on IOWN, which is the next-generation communication platform. In November 2021, we founded the Natural Society Lab to communicate how the technology incorporating IOWN will benefit society and enrich people's lives. We also create short films to convey to the masses our vision of a world where innovation in science and technology flourish alongside ideal human life.
Experts and filmmakers that took part in the conference included the Yubari International Fantastic Film Festival Executive Producer and Shinichiro Kumagaya, a professor from the Research Center for Advanced Science and Technology at the University of Tokyo. The conference included discussions on the following four topics:
Part 1: What is "Natural Society Lab"?
Part 2: Natural Society Lab & Daily Life - in the Context of Film & Science
Part 3: Creators' Take on Visualizing Thought
Part 4: Expressing the World Realized by IOWN
Conference Speakers:
Akiko Kudo
NTT Senior Vice President
Head of Public Relations
and Deputy Head of Business strategy*
*2022.June
Junji Watanabe
NTT Communication Science Laboratories
Senior Distinguished Research Scientist
Shinichiro Kumagaya
Pediatrician and
Associate Professor at the Research Center
for Advanced Science and Technology
Shuichi Fukatsu
Executive Producer
for Yubari International Fantastic Film Festival
Kristof Deak
Filmmaker
Genevieve Clay-Smith
Filmmaker
The short films selected and produced through the competition will be released next year.
1 IOWN (Innovative Optical and Wireless Network)
A future communication platform utilizing cutting-edge optical-related technology and information processing technology to realize a smart world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005622/en/
Contact information
Media Contact:
Committee for Short Shorts
PR Office (Tanaka)
press@shortshorts.org
NTT
Corporate Planning Dept., PR Office
ntt-cnr-ml@ntt.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 03:09:00 EEST | Press release
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio ha
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom